

Treatment Strategies for Dyslipidemia

This second part of a 3-part supplement series to *The American Journal of Managed Care* addresses various clinical and economic aspects of statin therapy in treating dyslipidemia.

Faculty

Lori Funk, PharmD

Clinical Pharmacist
Cape Fear Valley Health System
Highsmith-Rainey Memorial Hospital
Fayetteville, North Carolina

Robert M. Guthrie, MD

Professor
College of Medicine and Public Health
Ohio State University
Columbus, Ohio

Terrance Killilea, PharmD

Vice President of Pharmacy
Regence Blue Shield of Idaho
Boise, Idaho

James M. McKenney, PharmD

Professor Emeritus
Virginia Commonwealth University
President and Chief Executive Officer
National Clinical Research, Inc
Richmond, Virginia

Disclosure Statement

It is the policy of *The American Journal of Managed Care* to have all faculty who participate in programs sponsored by pharmaceutical organizations disclose any real or apparent conflicts of interest.

These participants report relationships with the following pharmaceutical companies:

■ **Robert M. Guthrie, MD**

Grant/Research support from:

Abbott Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
GlaxoSmithKline

Consultant for:

AstraZeneca

Speaker's bureau/Honorarium:

AstraZeneca

■ **James M. McKenney, PharmD**

Speaker's honoraria from:

AstraZeneca
KOS
Merck/Schering-Plough
Pfizer
Reliant

Research grant support from:

AstraZeneca
GlaxoSmithKline
KOS
Merck
Pfizer
Roche (research grant to National
Clinical Research, Inc)
Schering-Plough
Takeda

Consulting services provided for:

AstraZeneca
KOS
Microbia
Pfizer
Sankyo

The following participants have declared no financial affiliations with corporate organizations:

■ **Lori Funk, PharmD**

■ **Terrance Killilea, PharmD**

We would like to thank Wayne Kuznar for editorial assistance in the development of two of these articles (as noted in footnotes).

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Princeton, New Jersey.

Treatment Strategies for Dyslipidemia

Funding

This publication was made possible by a grant from **AstraZeneca**.



The contents of this supplement may include information regarding the use of products that may be inconsistent outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.